|
|
Post by compound26 on May 11, 2015 16:51:29 GMT -5
|
|
|
|
Post by compound26 on May 11, 2015 16:53:49 GMT -5
So there is some evidence that Sanofi and Mannkind did spend their marketing expenses in Q1.
|
|
|
|
Post by bioexec25 on May 11, 2015 17:30:00 GMT -5
Hehe. Yep. What a novel idea for the management team to mention and talk about these things from time to time. It begs the question of how many other things like this are out there that they know about and are mum on.
|
|
|
|
Post by ezrasfund on May 11, 2015 18:33:49 GMT -5
|
|
|
|
Post by compound26 on May 11, 2015 18:52:54 GMT -5
|
|
|
|
Post by liane on May 11, 2015 18:58:39 GMT -5
Nice find!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 11, 2015 19:24:21 GMT -5
This brings up an excellent point - patient outcomes is now squarely on the shoulders of the institutions that supply healthcare. I have a friend who provides consulting services to hospitals around the country and one of the programs he's been very active on is patient outcomes. He developed software to assist hospitals in tracking patient care from the moment they step in the front door until forever.....and it was driven by the ACA. Turns out, the ACA gives financial penalties to hospitals that, say as an example, have a patient that gets readmitted for the same issue within a limited but defined timeframe. That's had a chilling effect on hospital administrators due to the financial penalty. Interesting how this article taps into that as it relates to diabetes. thx for posting! |
|
|
|
Post by mnholdem on May 12, 2015 9:25:21 GMT -5
So there is some evidence that Sanofi and Mannkind did spend their marketing expenses in Q1. MannKind's Q1 share of expenses was around $12.5M meaning another $25M was paid by Sanofi. That's a bit much for doctors dinners and conferences (chuckle). The Griffin Securities reports (who just reiterated a BUY Rec with $16.25 target - see Resource folder for link) confirms that Sanofi has been spending on advertising to physicians prior to the DTC advertising expected to commence in July.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2015 9:26:13 GMT -5
So there is some evidence that Sanofi and Mannkind did spend their marketing expenses in Q1. MannKind's Q1 share of expenses was around $12.5M meaning another $25M was paid by Sanofi. That's a bit much for doctors dinners and conferences (chuckle). The Griffin Securities reports (BUY rec with target staying at $16.15) confirms that Sanofi has been spending on advertising to physicians prior to the DTC advertising expected to commence in July. because some of it was production costs kicking back. |
|
|
|
Post by yossarian on May 12, 2015 15:20:37 GMT -5
Something called Diabetes Health Pharmacist magazine has a cover story on AFREZZA t.co/vu9s2u9iYx |
|
